nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—prostate gland—urinary bladder cancer	0.053	0.167	CbGeAlD
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—LIG1—urinary bladder cancer	0.0492	0.242	CbGpPWpGaD
Plerixafor—CXCR4—seminal vesicle—urinary bladder cancer	0.0449	0.141	CbGeAlD
Plerixafor—CXCR4—epithelium—urinary bladder cancer	0.039	0.122	CbGeAlD
Plerixafor—CXCR4—smooth muscle tissue—urinary bladder cancer	0.0375	0.118	CbGeAlD
Plerixafor—CXCR4—renal system—urinary bladder cancer	0.0361	0.114	CbGeAlD
Plerixafor—CXCR4—urethra—urinary bladder cancer	0.0355	0.112	CbGeAlD
Plerixafor—CXCR4—female reproductive system—urinary bladder cancer	0.0289	0.091	CbGeAlD
Plerixafor—CXCR4—vagina—urinary bladder cancer	0.0262	0.0823	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF3—urinary bladder cancer	0.0231	0.114	CbGpPWpGaD
Plerixafor—CXCR4—lymph node—urinary bladder cancer	0.0169	0.0532	CbGeAlD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.00986	0.0485	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—RHOA—urinary bladder cancer	0.00907	0.0446	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—LIG1—urinary bladder cancer	0.00797	0.0392	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—RHOA—urinary bladder cancer	0.00745	0.0366	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—SRC—urinary bladder cancer	0.00664	0.0327	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—urinary bladder cancer	0.00591	0.0291	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.0059	0.0291	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—LIG1—urinary bladder cancer	0.00551	0.0271	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF1—urinary bladder cancer	0.00543	0.0267	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.00461	0.0227	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—urinary bladder cancer	0.00418	0.0206	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—RBX1—urinary bladder cancer	0.00398	0.0196	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—ERCC2—urinary bladder cancer	0.00353	0.0174	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—RHOA—urinary bladder cancer	0.00344	0.0169	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.00314	0.0155	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—urinary bladder cancer	0.00273	0.0134	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—SRC—urinary bladder cancer	0.00252	0.0124	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—ERCC2—urinary bladder cancer	0.00244	0.012	CbGpPWpGaD
Plerixafor—CXCR4—Disease—GSTO2—urinary bladder cancer	0.00235	0.0116	CbGpPWpGaD
Plerixafor—Immune system disorder—Cisplatin—urinary bladder cancer	0.00184	0.00384	CcSEcCtD
Plerixafor—CXCR4—Disease—SLC19A1—urinary bladder cancer	0.00183	0.00899	CbGpPWpGaD
Plerixafor—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00181	0.00378	CcSEcCtD
Plerixafor—Skin disorder—Thiotepa—urinary bladder cancer	0.00179	0.00374	CcSEcCtD
Plerixafor—CXCR4—Disease—PRSS3—urinary bladder cancer	0.00178	0.00876	CbGpPWpGaD
Plerixafor—Erythema—Cisplatin—urinary bladder cancer	0.00177	0.0037	CcSEcCtD
Plerixafor—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00176	0.00368	CcSEcCtD
Plerixafor—Flatulence—Cisplatin—urinary bladder cancer	0.00175	0.00365	CcSEcCtD
Plerixafor—Malaise—Gemcitabine—urinary bladder cancer	0.00171	0.00358	CcSEcCtD
Plerixafor—CXCR4—Disease—HDAC4—urinary bladder cancer	0.0017	0.00836	CbGpPWpGaD
Plerixafor—Immune system disorder—Etoposide—urinary bladder cancer	0.00168	0.00352	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00168	0.00351	CcSEcCtD
Plerixafor—Paraesthesia—Thiotepa—urinary bladder cancer	0.00166	0.00346	CcSEcCtD
Plerixafor—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00164	0.00343	CcSEcCtD
Plerixafor—Dyspepsia—Thiotepa—urinary bladder cancer	0.00162	0.00339	CcSEcCtD
Plerixafor—Arthralgia—Gemcitabine—urinary bladder cancer	0.00162	0.00338	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00161	0.00336	CcSEcCtD
Plerixafor—Discomfort—Gemcitabine—urinary bladder cancer	0.0016	0.00334	CcSEcCtD
Plerixafor—Malaise—Cisplatin—urinary bladder cancer	0.0016	0.00334	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00159	0.00332	CcSEcCtD
Plerixafor—Fatigue—Thiotepa—urinary bladder cancer	0.00159	0.00332	CcSEcCtD
Plerixafor—Pain—Thiotepa—urinary bladder cancer	0.00158	0.00329	CcSEcCtD
Plerixafor—Constipation—Thiotepa—urinary bladder cancer	0.00158	0.00329	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.00157	0.00774	CbGpPWpGaD
Plerixafor—Discomfort—Fluorouracil—urinary bladder cancer	0.00157	0.00328	CcSEcCtD
Plerixafor—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00155	0.00324	CcSEcCtD
Plerixafor—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00152	0.00319	CcSEcCtD
Plerixafor—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00152	0.00318	CcSEcCtD
Plerixafor—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00152	0.00317	CcSEcCtD
Plerixafor—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00151	0.00315	CcSEcCtD
Plerixafor—Skin disorder—Gemcitabine—urinary bladder cancer	0.00151	0.00315	CcSEcCtD
Plerixafor—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00151	0.00315	CcSEcCtD
Plerixafor—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.0015	0.00313	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.0015	0.00313	CcSEcCtD
Plerixafor—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.0015	0.00312	CcSEcCtD
Plerixafor—Discomfort—Cisplatin—urinary bladder cancer	0.00149	0.00311	CcSEcCtD
Plerixafor—Urticaria—Thiotepa—urinary bladder cancer	0.00146	0.00306	CcSEcCtD
Plerixafor—Malaise—Etoposide—urinary bladder cancer	0.00146	0.00306	CcSEcCtD
Plerixafor—Abdominal pain—Thiotepa—urinary bladder cancer	0.00146	0.00304	CcSEcCtD
Plerixafor—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00145	0.00302	CcSEcCtD
Plerixafor—Loss of consciousness—Etoposide—urinary bladder cancer	0.00143	0.00298	CcSEcCtD
Plerixafor—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00142	0.00296	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00141	0.00295	CcSEcCtD
Plerixafor—Skin disorder—Cisplatin—urinary bladder cancer	0.0014	0.00293	CcSEcCtD
Plerixafor—Insomnia—Gemcitabine—urinary bladder cancer	0.0014	0.00293	CcSEcCtD
Plerixafor—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.0014	0.00292	CcSEcCtD
Plerixafor—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00139	0.00291	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00139	0.0029	CcSEcCtD
Plerixafor—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00138	0.00289	CcSEcCtD
Plerixafor—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00138	0.00288	CcSEcCtD
Plerixafor—Insomnia—Fluorouracil—urinary bladder cancer	0.00138	0.00288	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00137	0.00287	CcSEcCtD
Plerixafor—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00137	0.00286	CcSEcCtD
Plerixafor—Discomfort—Etoposide—urinary bladder cancer	0.00136	0.00285	CcSEcCtD
Plerixafor—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00136	0.00284	CcSEcCtD
Plerixafor—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00136	0.00284	CcSEcCtD
Plerixafor—CXCR4—Disease—LIG1—urinary bladder cancer	0.00135	0.00664	CbGpPWpGaD
Plerixafor—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00134	0.0028	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00134	0.0028	CcSEcCtD
Plerixafor—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00134	0.00279	CcSEcCtD
Plerixafor—Fatigue—Gemcitabine—urinary bladder cancer	0.00134	0.00279	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.00133	0.00653	CbGpPWpGaD
Plerixafor—Constipation—Gemcitabine—urinary bladder cancer	0.00133	0.00277	CcSEcCtD
Plerixafor—Pain—Gemcitabine—urinary bladder cancer	0.00133	0.00277	CcSEcCtD
Plerixafor—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00132	0.00277	CcSEcCtD
Plerixafor—Asthenia—Thiotepa—urinary bladder cancer	0.00132	0.00276	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00132	0.00275	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00132	0.00275	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—urinary bladder cancer	0.00131	0.00275	CcSEcCtD
Plerixafor—Pruritus—Thiotepa—urinary bladder cancer	0.0013	0.00272	CcSEcCtD
Plerixafor—Pain—Fluorouracil—urinary bladder cancer	0.0013	0.00272	CcSEcCtD
Plerixafor—Paraesthesia—Cisplatin—urinary bladder cancer	0.0013	0.00271	CcSEcCtD
Plerixafor—Dyspnoea—Cisplatin—urinary bladder cancer	0.00129	0.00269	CcSEcCtD
Plerixafor—Skin disorder—Etoposide—urinary bladder cancer	0.00129	0.00269	CcSEcCtD
Plerixafor—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00128	0.00267	CcSEcCtD
Plerixafor—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00128	0.00267	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00128	0.00267	CcSEcCtD
Plerixafor—Diarrhoea—Thiotepa—urinary bladder cancer	0.00126	0.00264	CcSEcCtD
Plerixafor—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00126	0.00262	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00125	0.00261	CcSEcCtD
Plerixafor—Pain—Cisplatin—urinary bladder cancer	0.00124	0.00258	CcSEcCtD
Plerixafor—Dizziness—Thiotepa—urinary bladder cancer	0.00122	0.00255	CcSEcCtD
Plerixafor—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00122	0.00254	CcSEcCtD
Plerixafor—Urticaria—Fluorouracil—urinary bladder cancer	0.00121	0.00253	CcSEcCtD
Plerixafor—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00119	0.00249	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HDAC4—urinary bladder cancer	0.00119	0.00585	CbGpPWpGaD
Plerixafor—Paraesthesia—Etoposide—urinary bladder cancer	0.00119	0.00248	CcSEcCtD
Plerixafor—Dyspnoea—Etoposide—urinary bladder cancer	0.00118	0.00247	CcSEcCtD
Plerixafor—Vomiting—Thiotepa—urinary bladder cancer	0.00117	0.00245	CcSEcCtD
Plerixafor—Rash—Thiotepa—urinary bladder cancer	0.00116	0.00243	CcSEcCtD
Plerixafor—Dermatitis—Thiotepa—urinary bladder cancer	0.00116	0.00243	CcSEcCtD
Plerixafor—Headache—Thiotepa—urinary bladder cancer	0.00115	0.00241	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00114	0.00239	CcSEcCtD
Plerixafor—Fatigue—Etoposide—urinary bladder cancer	0.00114	0.00239	CcSEcCtD
Plerixafor—Pain—Etoposide—urinary bladder cancer	0.00113	0.00237	CcSEcCtD
Plerixafor—Constipation—Etoposide—urinary bladder cancer	0.00113	0.00237	CcSEcCtD
Plerixafor—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00112	0.00235	CcSEcCtD
Plerixafor—Haemoglobin—Methotrexate—urinary bladder cancer	0.00112	0.00234	CcSEcCtD
Plerixafor—Haemorrhage—Methotrexate—urinary bladder cancer	0.00112	0.00233	CcSEcCtD
Plerixafor—Asthenia—Gemcitabine—urinary bladder cancer	0.00111	0.00232	CcSEcCtD
Plerixafor—Pruritus—Gemcitabine—urinary bladder cancer	0.0011	0.00229	CcSEcCtD
Plerixafor—Nausea—Thiotepa—urinary bladder cancer	0.00109	0.00229	CcSEcCtD
Plerixafor—Feeling abnormal—Etoposide—urinary bladder cancer	0.00109	0.00228	CcSEcCtD
Plerixafor—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00108	0.00226	CcSEcCtD
Plerixafor—Pruritus—Fluorouracil—urinary bladder cancer	0.00108	0.00225	CcSEcCtD
Plerixafor—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00106	0.00222	CcSEcCtD
Plerixafor—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00106	0.00222	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.00105	0.00519	CbGpPWpGaD
Plerixafor—Urticaria—Etoposide—urinary bladder cancer	0.00105	0.0022	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—urinary bladder cancer	0.00105	0.00219	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—urinary bladder cancer	0.00105	0.00219	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—urinary bladder cancer	0.00104	0.00218	CcSEcCtD
Plerixafor—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00104	0.00218	CcSEcCtD
Plerixafor—Asthenia—Cisplatin—urinary bladder cancer	0.00104	0.00217	CcSEcCtD
Plerixafor—CXCR4—Disease—ENO2—urinary bladder cancer	0.00103	0.00507	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00103	0.00214	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—urinary bladder cancer	0.00101	0.00211	CcSEcCtD
Plerixafor—Dizziness—Fluorouracil—urinary bladder cancer	0.00101	0.00211	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GLI1—urinary bladder cancer	0.000997	0.00491	CbGpPWpGaD
Plerixafor—Diarrhoea—Cisplatin—urinary bladder cancer	0.000989	0.00207	CcSEcCtD
Plerixafor—Vomiting—Gemcitabine—urinary bladder cancer	0.000986	0.00206	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—urinary bladder cancer	0.000978	0.00204	CcSEcCtD
Plerixafor—Rash—Gemcitabine—urinary bladder cancer	0.000978	0.00204	CcSEcCtD
Plerixafor—Dermatitis—Gemcitabine—urinary bladder cancer	0.000977	0.00204	CcSEcCtD
Plerixafor—Hypersensitivity—Etoposide—urinary bladder cancer	0.000976	0.00204	CcSEcCtD
Plerixafor—CXCR4—Disease—RBX1—urinary bladder cancer	0.000976	0.0048	CbGpPWpGaD
Plerixafor—Erythema—Methotrexate—urinary bladder cancer	0.000972	0.00203	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000972	0.00203	CcSEcCtD
Plerixafor—Headache—Gemcitabine—urinary bladder cancer	0.000971	0.00203	CcSEcCtD
Plerixafor—Vomiting—Fluorouracil—urinary bladder cancer	0.000969	0.00203	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000967	0.00202	CcSEcCtD
Plerixafor—Rash—Fluorouracil—urinary bladder cancer	0.000961	0.00201	CcSEcCtD
Plerixafor—Dermatitis—Fluorouracil—urinary bladder cancer	0.00096	0.00201	CcSEcCtD
Plerixafor—Headache—Fluorouracil—urinary bladder cancer	0.000955	0.002	CcSEcCtD
Plerixafor—Asthenia—Etoposide—urinary bladder cancer	0.00095	0.00198	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00095	0.00198	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—urinary bladder cancer	0.000944	0.00197	CcSEcCtD
Plerixafor—Pruritus—Etoposide—urinary bladder cancer	0.000937	0.00196	CcSEcCtD
Plerixafor—Nausea—Gemcitabine—urinary bladder cancer	0.000921	0.00192	CcSEcCtD
Plerixafor—Vomiting—Cisplatin—urinary bladder cancer	0.000919	0.00192	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—urinary bladder cancer	0.000915	0.00191	CcSEcCtD
Plerixafor—Rash—Cisplatin—urinary bladder cancer	0.000911	0.0019	CcSEcCtD
Plerixafor—Dermatitis—Cisplatin—urinary bladder cancer	0.000911	0.0019	CcSEcCtD
Plerixafor—Erythema—Epirubicin—urinary bladder cancer	0.000909	0.0019	CcSEcCtD
Plerixafor—Diarrhoea—Etoposide—urinary bladder cancer	0.000906	0.00189	CcSEcCtD
Plerixafor—Nausea—Fluorouracil—urinary bladder cancer	0.000906	0.00189	CcSEcCtD
Plerixafor—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000902	0.00188	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—urinary bladder cancer	0.000896	0.00187	CcSEcCtD
Plerixafor—Malaise—Methotrexate—urinary bladder cancer	0.000876	0.00183	CcSEcCtD
Plerixafor—Dizziness—Etoposide—urinary bladder cancer	0.000876	0.00183	CcSEcCtD
Plerixafor—CXCR4—Disease—JAG1—urinary bladder cancer	0.000873	0.0043	CbGpPWpGaD
Plerixafor—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000873	0.00182	CcSEcCtD
Plerixafor—Nausea—Cisplatin—urinary bladder cancer	0.000859	0.00179	CcSEcCtD
Plerixafor—Mental disorder—Doxorubicin—urinary bladder cancer	0.000847	0.00177	CcSEcCtD
Plerixafor—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000844	0.00176	CcSEcCtD
Plerixafor—Vomiting—Etoposide—urinary bladder cancer	0.000842	0.00176	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—urinary bladder cancer	0.000842	0.00176	CcSEcCtD
Plerixafor—Rash—Etoposide—urinary bladder cancer	0.000835	0.00174	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—urinary bladder cancer	0.000834	0.00174	CcSEcCtD
Plerixafor—Headache—Etoposide—urinary bladder cancer	0.00083	0.00173	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—urinary bladder cancer	0.000829	0.00173	CcSEcCtD
Plerixafor—Arthralgia—Methotrexate—urinary bladder cancer	0.000827	0.00173	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000822	0.00172	CcSEcCtD
Plerixafor—Malaise—Epirubicin—urinary bladder cancer	0.00082	0.00171	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—urinary bladder cancer	0.000817	0.00171	CcSEcCtD
Plerixafor—Syncope—Epirubicin—urinary bladder cancer	0.000816	0.0017	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000803	0.00395	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000799	0.00167	CcSEcCtD
Plerixafor—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000793	0.00166	CcSEcCtD
Plerixafor—Nausea—Etoposide—urinary bladder cancer	0.000787	0.00164	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000781	0.00163	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000778	0.00163	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—urinary bladder cancer	0.000774	0.00162	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—urinary bladder cancer	0.00077	0.00161	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000769	0.00161	CcSEcCtD
Plerixafor—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000767	0.0016	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—urinary bladder cancer	0.000765	0.0016	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—urinary bladder cancer	0.000759	0.00159	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—urinary bladder cancer	0.000757	0.00158	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—urinary bladder cancer	0.000755	0.00158	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000742	0.00155	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00074	0.00155	CcSEcCtD
Plerixafor—Shock—Epirubicin—urinary bladder cancer	0.00073	0.00153	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000728	0.00152	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000723	0.00151	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—urinary bladder cancer	0.000721	0.00151	CcSEcCtD
Plerixafor—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000718	0.0015	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—urinary bladder cancer	0.000717	0.0015	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—urinary bladder cancer	0.000716	0.0015	CcSEcCtD
Plerixafor—Paraesthesia—Methotrexate—urinary bladder cancer	0.000712	0.00149	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000712	0.00149	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—urinary bladder cancer	0.000708	0.00148	CcSEcCtD
Plerixafor—Dyspnoea—Methotrexate—urinary bladder cancer	0.000707	0.00148	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—urinary bladder cancer	0.000701	0.00146	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—urinary bladder cancer	0.000698	0.00146	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000687	0.00143	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000685	0.00143	CcSEcCtD
Plerixafor—Fatigue—Methotrexate—urinary bladder cancer	0.000684	0.00143	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RBX1—urinary bladder cancer	0.000683	0.00336	CbGpPWpGaD
Plerixafor—Pain—Methotrexate—urinary bladder cancer	0.000678	0.00142	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000676	0.00141	CcSEcCtD
Plerixafor—Shock—Doxorubicin—urinary bladder cancer	0.000676	0.00141	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000674	0.00141	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—urinary bladder cancer	0.000671	0.0014	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—urinary bladder cancer	0.000667	0.00139	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—urinary bladder cancer	0.000667	0.00139	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000664	0.00139	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—urinary bladder cancer	0.000662	0.00138	CcSEcCtD
Plerixafor—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000654	0.00137	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—urinary bladder cancer	0.000653	0.00137	CcSEcCtD
Plerixafor—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000649	0.00136	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TSC1—urinary bladder cancer	0.000642	0.00316	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000641	0.00134	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—urinary bladder cancer	0.00064	0.00134	CcSEcCtD
Plerixafor—CXCR4—Disease—NCOR1—urinary bladder cancer	0.000636	0.00313	CbGpPWpGaD
Plerixafor—Constipation—Epirubicin—urinary bladder cancer	0.000635	0.00133	CcSEcCtD
Plerixafor—Pain—Epirubicin—urinary bladder cancer	0.000635	0.00133	CcSEcCtD
Plerixafor—Urticaria—Methotrexate—urinary bladder cancer	0.00063	0.00132	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—urinary bladder cancer	0.000627	0.00131	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000626	0.00131	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—urinary bladder cancer	0.000621	0.0013	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000617	0.00129	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000612	0.00128	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000612	0.00128	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JAG1—urinary bladder cancer	0.000611	0.00301	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000607	0.00127	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000605	0.00126	CcSEcCtD
Plerixafor—CXCR4—Disease—ERCC2—urinary bladder cancer	0.000598	0.00294	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000593	0.00124	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—urinary bladder cancer	0.000592	0.00124	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—urinary bladder cancer	0.00059	0.00123	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—urinary bladder cancer	0.000587	0.00123	CcSEcCtD
Plerixafor—Pain—Doxorubicin—urinary bladder cancer	0.000587	0.00123	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—urinary bladder cancer	0.000587	0.00123	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000584	0.00122	CcSEcCtD
Plerixafor—Asthenia—Methotrexate—urinary bladder cancer	0.000569	0.00119	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000566	0.00118	CcSEcCtD
Plerixafor—CXCR4—Disease—MTHFR—urinary bladder cancer	0.000562	0.00277	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000562	0.00117	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—urinary bladder cancer	0.000561	0.00117	CcSEcCtD
Plerixafor—CXCR4—Disease—TERT—urinary bladder cancer	0.00056	0.00276	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000547	0.00114	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—urinary bladder cancer	0.000546	0.00114	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000543	0.00113	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—urinary bladder cancer	0.000543	0.00113	CcSEcCtD
Plerixafor—Asthenia—Epirubicin—urinary bladder cancer	0.000533	0.00111	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—urinary bladder cancer	0.000525	0.0011	CcSEcCtD
Plerixafor—Dizziness—Methotrexate—urinary bladder cancer	0.000525	0.0011	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000517	0.00254	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGFR3—urinary bladder cancer	0.000514	0.00253	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—urinary bladder cancer	0.000508	0.00106	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000506	0.00106	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—urinary bladder cancer	0.000504	0.00105	CcSEcCtD
Plerixafor—Rash—Methotrexate—urinary bladder cancer	0.0005	0.00104	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—urinary bladder cancer	0.0005	0.00104	CcSEcCtD
Plerixafor—Headache—Methotrexate—urinary bladder cancer	0.000497	0.00104	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—S100B—urinary bladder cancer	0.000495	0.00244	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—urinary bladder cancer	0.000493	0.00103	CcSEcCtD
Plerixafor—Dizziness—Epirubicin—urinary bladder cancer	0.000491	0.00103	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—urinary bladder cancer	0.000486	0.00102	CcSEcCtD
Plerixafor—Vomiting—Epirubicin—urinary bladder cancer	0.000472	0.000986	CcSEcCtD
Plerixafor—Nausea—Methotrexate—urinary bladder cancer	0.000471	0.000984	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00047	0.000982	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—RHOA—urinary bladder cancer	0.000469	0.00231	CbGpPWpGaD
Plerixafor—Rash—Epirubicin—urinary bladder cancer	0.000468	0.000978	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—urinary bladder cancer	0.000468	0.000977	CcSEcCtD
Plerixafor—Headache—Epirubicin—urinary bladder cancer	0.000465	0.000971	CcSEcCtD
Plerixafor—Dizziness—Doxorubicin—urinary bladder cancer	0.000454	0.000949	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000454	0.00223	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NCOR1—urinary bladder cancer	0.000445	0.00219	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—urinary bladder cancer	0.000441	0.000921	CcSEcCtD
Plerixafor—CXCR4—Disease—CREBBP—urinary bladder cancer	0.000438	0.00215	CbGpPWpGaD
Plerixafor—Vomiting—Doxorubicin—urinary bladder cancer	0.000437	0.000912	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—urinary bladder cancer	0.000434	0.00213	CbGpPWpGaD
Plerixafor—Rash—Doxorubicin—urinary bladder cancer	0.000433	0.000905	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—urinary bladder cancer	0.000433	0.000904	CcSEcCtD
Plerixafor—Headache—Doxorubicin—urinary bladder cancer	0.00043	0.000899	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000412	0.00203	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—urinary bladder cancer	0.000408	0.000852	CcSEcCtD
Plerixafor—CXCR4—Disease—RHOA—urinary bladder cancer	0.000396	0.00195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL2—urinary bladder cancer	0.000394	0.00194	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—urinary bladder cancer	0.000392	0.00193	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—urinary bladder cancer	0.000367	0.0018	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR3—urinary bladder cancer	0.00036	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—urinary bladder cancer	0.000358	0.00176	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—urinary bladder cancer	0.00035	0.00172	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—urinary bladder cancer	0.000313	0.00154	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—urinary bladder cancer	0.000313	0.00154	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CREBBP—urinary bladder cancer	0.000307	0.00151	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1—urinary bladder cancer	0.000303	0.00149	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—urinary bladder cancer	0.000301	0.00148	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EP300—urinary bladder cancer	0.000298	0.00147	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SRC—urinary bladder cancer	0.00029	0.00143	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—urinary bladder cancer	0.000285	0.0014	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RHOA—urinary bladder cancer	0.000277	0.00136	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—urinary bladder cancer	0.00026	0.00128	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—urinary bladder cancer	0.000257	0.00126	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—urinary bladder cancer	0.000254	0.00125	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—urinary bladder cancer	0.000243	0.0012	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—urinary bladder cancer	0.000242	0.00119	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—urinary bladder cancer	0.00024	0.00118	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—urinary bladder cancer	0.000233	0.00115	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—urinary bladder cancer	0.000227	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—urinary bladder cancer	0.00022	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000219	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—urinary bladder cancer	0.000219	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EP300—urinary bladder cancer	0.000209	0.00103	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—urinary bladder cancer	0.000204	0.001	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—urinary bladder cancer	0.000203	0.000999	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—urinary bladder cancer	0.000182	0.000895	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—urinary bladder cancer	0.000178	0.000876	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—urinary bladder cancer	0.000168	0.000827	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—urinary bladder cancer	0.000149	0.000735	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—urinary bladder cancer	0.000143	0.000703	CbGpPWpGaD
